Gilder Gagnon Howe & Co’s Regulus Therapeutics RGLS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-62	Closed	-$120K	–	278
2014 Q4	$120K	Buy	+62	New	+$110K	﹤0.01%	241

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gilder Gagnon Howe & Co's RGLS Position: Q1 2015 in Review

Gilder Gagnon Howe & Co sold out of Regulus Therapeutics (RGLS) in Q1 2015, closing a stake of 62 shares — an estimated $120K sold.

Gilder Gagnon Howe & Co first reported a position in RGLS in Q4 2014 and held it in 1 quarter. The position peaked at $120K in Q4 2014. 88 funds tracked by Wall St. Rank hold RGLS as of Q1 2015.

Gilder Gagnon Howe & Co reported no remaining Regulus Therapeutics position as of Q1 2015 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 62 Regulus Therapeutics shares in Q1 2015, an estimated $120K.
Gilder Gagnon Howe & Co first reported a position in Regulus Therapeutics in Q4 2014 and held it in 1 quarter.
Gilder Gagnon Howe & Co's Regulus Therapeutics position peaked at $120K in Q4 2014.
88 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2015, filed 30 Apr 2015.